(7-methoxybenzofuran-2-yl)boronic acid | 1094417-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (7-methoxybenzofuran-2-yl)boronic acid
• 英文别名: (7-methoxy-1-benzofuran-2-yl)boronic acid
• CAS: 1094417-81-8
• 化学式: C₉H₉BO₄
• mdl: MFCD16547519
• 分子量: 191.979
• InChiKey: DZPWZFCRQSOJOO-UHFFFAOYSA-N

物化性质

• 沸点：
  377.1±45.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.61
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  62.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (7-methoxybenzofuran-2-yl)boronic acid 在 2,2,6,6-tetramethylpiperidine-1-oxoammonium tetrafluoroborate 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 0.34h， 生成 1-(7-methoxybenzofuran-2-yl)-2-(pyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors

  摘要：

  Based on perlolyrine (1), a natural alkaloid with weak PDE5 potency from the traditional Chinese aphrodisiac plant Tribulus terrestris L., a series alpha-substituted tetrahydro-beta-carboline (TH beta C) derivatives were synthesized via T(+)BF4(-)-mediated oxidative C-H functionalization of N-aryl TH beta Cs with diverse potassium trifluoroborates. Following Winterfeldt oxidation afforded the corresponding furyl/thienyl pyrroloquinolones, of which 5-ethylthiophene/ethylfuran derivatives 20a-b were identified as the most potent and selective PDE5 inhibitors. Among the enantiomers, (S)-20a and (S)-20b (IC50 = 0.52 and 0.39 nM) were found to be more effective than their (R)-antipode, display favorable pharmacokinetic profiles, exert in vitro vasorelaxant effects on the isolated thoracic aorta, and exhibit in vivo efficacy in the anesthetized rabbit erectile model. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.02.039
• 作为产物：
  描述：

  7-甲氧基苯并呋喃 、 硼酸三甲酯 、 水 在 正丁基锂 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.83h， 生成 (7-methoxybenzofuran-2-yl)boronic acid
  参考文献：
  名称：

  Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors

  摘要：

  Based on perlolyrine (1), a natural alkaloid with weak PDE5 potency from the traditional Chinese aphrodisiac plant Tribulus terrestris L., a series alpha-substituted tetrahydro-beta-carboline (TH beta C) derivatives were synthesized via T(+)BF4(-)-mediated oxidative C-H functionalization of N-aryl TH beta Cs with diverse potassium trifluoroborates. Following Winterfeldt oxidation afforded the corresponding furyl/thienyl pyrroloquinolones, of which 5-ethylthiophene/ethylfuran derivatives 20a-b were identified as the most potent and selective PDE5 inhibitors. Among the enantiomers, (S)-20a and (S)-20b (IC50 = 0.52 and 0.39 nM) were found to be more effective than their (R)-antipode, display favorable pharmacokinetic profiles, exert in vitro vasorelaxant effects on the isolated thoracic aorta, and exhibit in vivo efficacy in the anesthetized rabbit erectile model. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.02.039

文献信息

• [EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013774A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  公开了公式(I)至(VIII)的化合物：(I) (II) (III) (IV) (V) (VI) (VII) (VIII)；或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R3是与0至3个R3a取代的双环杂芳基团；且R1、R2、R3a、R4和n在此定义。还公开了使用这些化合物作为PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物用于抑制或预防血小板聚集，用于治疗血栓栓塞障碍或作为血栓栓塞障碍的初级预防。
• Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis
  作者：Xiaojun Zhang、Wen Jiang、Jeremy M. Richter、J. Alex Bates、Samuel K. Reznik、Sylwia Stachura、Richard Rampulla、Dyamanna Doddalingappa、Sankar Ulaganathan、Ji Hua、Jeffrey S. Bostwick、Chi Sum、Shana Posy、Sarah Malmstrom、Joyce Dickey、David Harden、R. Michael Lawrence、Victor R. Guarino、William A. Schumacher、Pancras Wong、Jing Yang、David A. Gordon、Ruth R. Wexler、E. Scott Priestley

  DOI：10.1021/acs.jmedchem.3c01986

  日期：2024.3.14

  led to the discovery of a quinoxaline-benzothiazole series as potent and selective PAR4 antagonists. The lead compound 48, possessing a 2 nM IC50 against PAR4 activation by γ-thrombin in platelet-rich plasma (PRP) and greater than 2500-fold selectivity versus PAR1, demonstrated robust antithrombotic efficacy and minimal bleeding in the cynomolgus monkey models.

  PAR4 是一种有前景的抗血栓靶点，相对于当前的抗血小板治疗，具有将疗效与出血风险分开的潜力。为了发现一种新型 PAR4 拮抗剂化学型，我们鉴定出了一种基于喹喔啉的 HTS hit 3 ，具有低 μM 效力。通过使用位置 SAR 扫描和构象约束核心的设计来优化 HTS 命中，导致发现了喹喔啉-苯并噻唑系列作为有效的选择性 PAR4 拮抗剂。先导化合物48在富含血小板的血浆 (PRP) 中对 γ-凝血酶激活 PAR4 具有 2 nM IC 50 ，且选择性相对于 PAR1 超过 2500 倍，在食蟹猴模型中表现出强大的抗血栓功效和最少的出血。